Drug Development

Feliza Mirasol is the science editor for 

Videos

Ken Keller, president and CEO, Daiichi Sankyo, discusses the foundation of partnership and takes a look at the future of biotech partnerships at the US Pharma and Biotech Summit.

A Look at the Future of Bio/Pharma Partnerships at the US Pharma and Biotech Summit

Articles

At CPHI NA, Rachel Harris, AstraZeneca, spoke on her work at BioPhorum to enable industry consensus and action for sustainability with drug delivery devices.

Embedding Sustainability in Drug Delivery through Industry Consensus at CPHI NA

The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.

Regeneron Presents Update on Gene Therapy for Genetic Deafness at ASGCT

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics. 

Biologics on Target for the Future

Cheryl Barton is director of PharmaVision, 

Novel delivery technologies enhance brain penetration to target neurodegenerative diseases and glioblastomas.

Frontrunners in CNS Drug Delivery

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

The use of appropriate taste-masking and appearance technologies can facilitate patient compliance.

Using Taste-Masking and Appearance to Address Patient-Specific Needs

Tao Peng, PhD, is biopharma research manager at Roquette.

A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.

Polysorbates: Part(icle) of the Problem?

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

In this exclusive Drug Digest video interview, Chris Spivey, Director, Industry Relations and Strategic Partnerships, talks with industry experts about various aspects of drug product stability testing.

Drug Digest: Is Our Understanding of Stability Changing

Mike Hennessy Jr. is the Chairman and CEO of 

Technological advances are helping advance biologics development and manufacturing and reduce bottlenecks.

Tapping into the Potential of Biologics

A tidal wave of questions floats the need for more upstream automation.

Formulation and Drug Delivery